ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms

References

• Arber DA , OraziA, HasserjianRet al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood127(20), 2391–2405 (2016).
   PubMed Web of Science ®Google Scholar
• Mesa RA , LiC-YY, KetterlingRP, SchroederGS, KnudsonRA, TefferiA. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood105(3), 973–977 (2005).
   PubMed Web of Science ®Google Scholar
• Mascarenhas J . A concise update on risk factors, therapy, and outcome of leukemic transformation of myeloproliferative neoplasms. Clin. Lymphoma Myeloma Leuk.16, S124–S129 (2016).
   PubMed Web of Science ®Google Scholar
• Tefferi A , MudireddyM, MannelliFet al. Blast phase myeloproliferative neoplasm: Mayo–AGIMM study of 410 patients from two separate cohorts. Leukemia32(5), 1200–1210 (2018).
   PubMed Web of Science ®Google Scholar
• Cervantes F , TassiesD, SalgadoC, RoviraM, PereiraA, RozmanC. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol.85(3), 124–127 (1991).
   PubMed Web of Science ®Google Scholar
• Tam CS , NussenzveigRM, PopatUet al. The natural history and treatment outcome of blast phase BCR-ABL− myeloproliferative neoplasms. Blood112(5), 1628–1637 (2008).
   PubMed Web of Science ®Google Scholar
• Kennedy JA , AtenafuEG, MessnerHAet al. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood121(14), 2725–2733 (2013).
   PubMed Web of Science ®Google Scholar
• Cahu X , ChevallierP, ClavertAet al. Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant.49(6), 756–760 (2014).
   PubMed Web of Science ®Google Scholar
• Andriani A , MontanaroM, VosoMTet al. Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. Leuk. Res.39(8), 801–804 (2015).
   PubMed Web of Science ®Google Scholar
• Badar T , KantarjianHM, RavandiFet al. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leuk. Res.39(9), 950–956 (2015).
   PubMed Web of Science ®Google Scholar
• Thepot S , ItzyksonR, SeegersVet al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood116(19), 3735–3742 (2010).
   PubMed Web of Science ®Google Scholar
• Konopleva M , PollyeaDA, PotluriJet al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov.6(10), 1106–1117 (2016).
   PubMed Web of Science ®Google Scholar
• DiNardo CD , RauschCR, BentonCet al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am. J. Hematol.93(3), 401–407 (2018).
   PubMed Web of Science ®Google Scholar
• DiNardo CD , PratzK, PullarkatVet al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood133(1), 7–17 (2018).
   PubMed Web of Science ®Google Scholar
• Pollyea DA , PratzKW, JonasBAet al. Venetoclax in combination with hypomethylating agents induces rapid, deep, and durable responses in patients with AML ineligible for intensive therapy. Blood132(Suppl. 1), 285–285 (2018).
   Google Scholar
• Wei AH , JrSAS, HouJ-Zet al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J. Clin. Oncol.37(15), 1277–1284 (2019).
   PubMed Web of Science ®Google Scholar
• DiNardo CD , PratzKW, LetaiAet al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol.19(2), 216–228 (2018).
   PubMed Web of Science ®Google Scholar
• Aldoss I , YangD, AribiAet al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Haematologica103(9), e404–e407 (2018).
   PubMed Web of Science ®Google Scholar
• Wei AH , MontesinosP, IvanovVet al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood135(24), 2137–2145 (2020).
   PubMed Web of Science ®Google Scholar
• DiNardo CD , JonasBA, PullarkatVet al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl. J. Med.383(7), 617–629 (2020).
   PubMed Web of Science ®Google Scholar
• Ciurea SO , de LimaM, GiraltSet al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol. Blood Marrow Transplant.16(4), 555–559 (2010).
   PubMed Web of Science ®Google Scholar
• Alchalby H , ZabelinaT, StübigTet al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. Biol. Blood Marrow Transplant.20(2), 279–281 (2014).
   PubMed Web of Science ®Google Scholar
• Takagi S , MasuokaK, UchidaNet al. Allogeneic hematopoietic cell transplantation for leukemic transformation preceded by Philadelphia chromosome-negative myeloproliferative neoplasms: a nationwide survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol. Blood Marrow Transplant.22(12), 2208–2213 (2016).
   PubMed Web of Science ®Google Scholar
• Guglielmelli P , LashoTL, RotunnoGet al. MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis. J. Clin. Oncol.36(4), 310–318 (2017).
   PubMed Web of Science ®Google Scholar
• Green A , BeerP. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N. Engl. J. Med.362(4), 369–370 (2010).
   PubMed Web of Science ®Google Scholar
• Pardanani A , LashoT, FinkeC, MaiM, McClureR, TefferiA. IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia24(6), 1146–1151 (2010).
   PubMed Web of Science ®Google Scholar
• Harutyunyan A , KlampflT, CazzolaM, KralovicsR. p53 lesions in leukemic transformation. N. Engl. J. Med.364(5), 488–490 (2011).
   PubMed Web of Science ®Google Scholar
• Lundberg P , KarowA, NienholdRet al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood123(14), 2220–2228 (2014).
   PubMed Web of Science ®Google Scholar
• Welch JS , PettiAA, MillerCAet al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N. Engl. J. Med.375(21), 2023–2036 (2016).
   PubMed Web of Science ®Google Scholar
• King AC , WeisTM, DerkachAet al. Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms. Am. J. Hematol.97(1), E7–E10 (2021).
   PubMed Web of Science ®Google Scholar
• Masarova L , DiNardoCD, BosePet al. Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Adv.5(8), 2156–2164 (2021).
   PubMed Web of Science ®Google Scholar
• Tremblay D , FeldJ, DoughertyMet al. Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm. Leuk. Res.98, 106456 (2020).
   PubMed Web of Science ®Google Scholar
• Gangat N , GuglielmelliP, SzuberNet al. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases. Am. J. Hematol.96(7), 781–789 (2021).
   PubMed Web of Science ®Google Scholar
• Gangat N , MorsiaE, ForanJM, PalmerJM, ElliottMA, TefferiA. Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients. Br. J. Haematol.191(5), e120–e124 (2020).
   PubMed Web of Science ®Google Scholar
• Jonas BA , PollyeaDA. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia33(12), 2795–2804 (2019).
   PubMed Web of Science ®Google Scholar
• Mascarenhas J , HeaneyML, NajfeldVet al. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leuk. Res.36(12), 1500–1504 (2012).
   PubMed Web of Science ®Google Scholar
• A’Hern RP . Sample size tables for exact single-stage phase II designs. Stat. Med.20(6), 859–866 (2001).
   PubMed Web of Science ®Google Scholar
• Döhner H , EsteyE, GrimwadeDet al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood129(4), 424–447 (2017).
   PubMed Web of Science ®Google Scholar
• Ding L , LeyTJ, LarsonDEet al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature481(7382), 506–510 (2012).
   PubMed Web of Science ®Google Scholar
• Garg M , NagataY, KanojiaDet al. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood126(22), 2491–2501 (2015).
   PubMed Web of Science ®Google Scholar